Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

This study found that monitoring endogenous steroid metabolites in serum may improve the detection of testosterone doping by highlighting promising biomarkers.

This study suggests that epitestosterone may play a role in regulating androgen-dependent processes like prostate growth and body hair distribution by counteracting testosterone's actions.

This retrospective analysis reported significant increases in testosterone levels in men with testosterone deficiency using the Daily Subcutaneous Testosterone method combined with hCG and anastrozole, indicating its potential as a treatment option.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

In this study, engineered mice with a mutation similar to that in Olmsted syndrome showed progressive hair loss due to impaired inner root sheath keratinocyte differentiation and stem cell exhaustion.

This study found that oral estradiol was generally effective in achieving target 17-β estradiol levels in transgender women, but often failed to suppress testosterone adequately, with variability in individual responses.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This chapter reviews the biosynthesis, mechanism of action, and therapeutic effects of testosterone and related androgens, but reports no new research findings.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This study found that epitestosterone acts as a weak antiandrogen by inhibiting receptor binding and 5α-reductase activity in animal models.

In this study, female-to-male transsexuals treated with long-acting testosterone undecanoate experienced an increase in lean mass but no change in fat mass or bone mineral density over 24 months.

The body's change of testosterone into DHT is not necessary for testosterone's muscle and sexual effects.

In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.

This study reports a case of an ovarian steroid cell tumor with malignant potential, presenting unusually with osteopenia and low weight instead of the expected virilizing symptoms.

New treatments for male hypogonadism are effective and should be personalized.

The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.

This research suggests that fluoxymesterone, an anabolic steroid, may inhibit a key enzyme, potentially contributing to cardiovascular issues by affecting cortisol's activation of mineralocorticoid receptors.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

This review discusses testosterone replacement therapy, highlighting that most studies report no increased myocardial infarction risk when the therapy is properly administered with controlled hormone levels; it calls for careful consideration despite insurance coverage challenges.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

This review discusses the controversial cardiovascular safety and efficacy of subcutaneous testosterone therapy in postmenopausal women, noting that its long-term use appears safe, but CV risk assessments remain disputed.

This study found that in male androgenic alopecia, the androgen receptor coactivator ARA70/ELE1 exhibits differential expression patterns, suggesting its involvement in the condition.